MAIGRET: a CRISPR-based immunoassay that employs antibody-induced cell-free transcription of CRISPR guide RNA strands

26 July 2024, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Here we report on the development of a CRISPR-based assay for the sensitive and specific detection of antibodies and antigens directly in complex sample matrices. The assay, called MAIGRET (Molecular Assay based on antibody-Induced Guide-RNA Enzymatic Transcription), is based on the use of a responsive synthetic DNA template that trigger the cell-free in vitro transcription of a guide RNA strand upon recognition of a specific target antibody. Such transcribed guide RNA activates the DNA collateral activity of the Cas12 enzyme, leading to the downstream cleavage of a fluorophore/quencher-labelled reporter and thus resulting in an increase in the measured fluorescence signal. We have used MAIGRET for the detection of six different antibodies with high sensitivity (detection limit in the picomolar range) and specificity (no signal in the presence of non-target antibodies). MAIGRET can also be adapted to a competitive approach for the detection of specific antigens. With MAIGRET we significantly expand the scope and applicability of CRISPR-based sensing approaches to potentially enable the measurement of any molecular target for which an antibody is available.

Keywords

CRISPR
DNA Nanotechnology
Cell-free transcription
Biosensors
Immunoassay

Supplementary materials

Title
Description
Actions
Title
Supplementary Information
Description
Experimental methods; DNA sequences; supplementary figures
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.